Ecallantide National NME Drug Monograph

In EDEMA3, there was a greater improvement in the primary endpoint of TOS (ecallantide: median 50.0 [interquartile range or IQR 0 to 100], mean 46.8 [standard deviation or SD 59.34] vs. placebo: median 0 [IQR 0 to 100], mean 21.3 [SD 69.04]; P=0.004) and greater decrease from baseline in the secondary endpoint MSCS score at 4 hours (ecallantide ... ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download